Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Sentieon
AddedFeb 15, 2024
UpdatedJun 18, 2026
Sentieon

Sentieon

Series B

Sentieon offers efficient, scalable cloud-based bioinformatics solutions for life sciences, specializing in genomics data analysis.

HQ
Mountain View, CA, US
Founded
2014
Overview
Compare
Fundraising
Employees
Website

Sentieon develops and provides advanced bioinformatics solutions for genomics data analysis in the life sciences and clinical sectors. Their suite of secondary analysis tools processes genomic data with high efficiency, speed, and accuracy. The company's flagship products include Sentieon DNAseq for germline DNA analysis and Sentieon TNseq for tumor-normal somatic variant detection, offering scalable and upgradable solutions for various genomic applications.

Sentieon's technology accelerates genomic data processing through CPU/ARM optimization, providing drop-in replacements and improvements for industry-standard tools like BWA-MEM, STAR, Minimap2, GATK, and Mutect2. Their DNAscope pipeline supports both short and long-read sequencing data, enabling comprehensive genomic analysis. Sentieon's innovations contribute to advancing precision medicine by enhancing the speed and accuracy of genomic data interpretation.

Sentieon - Similar Companies

Basepair logo

Basepair

basepairtech.com

Dnanexus logo

Dnanexus

dnanexus.com

GenomeNext logo

GenomeNext

Genomenon logo

Genomenon

genomenon.com

BioTuring logo

BioTuring

bioturing.com

Seven Bridges logo

Seven Bridges

sevenbridges.com

Sequegenics logo

Sequegenics

sequegenics.com

Geneformics logo

Geneformics

Streamline Genomics logo

Streamline Genomics

Era7 Bioinformatics logo

Era7 Bioinformatics

Gencove logo

Gencove

gencove.com

Sequencing.com logo

Sequencing.com

sequencing.com

Bioinfoexperts logo

Bioinfoexperts

bioinfox.com

Station X logo

Station X

Data Driven Bioscience logo

Data Driven Bioscience

Sentieon - Quick Facts

Who are Sentieon's competitors?

Companies similar to Sentieon include Basepair, Dnanexus, GenomeNext and Genomenon.

When was Sentieon founded?

Sentieon was founded in 2014.

Where is Sentieon's headquarters located?

Sentieon's headquarters is located in Mountain View, CA, US.

When was Sentieon's last funding round?

Sentieon's most recent funding round was for $20M (USD) in May 2015.

How much has Sentieon raised to-date?

As of May 25, 2015, Sentieon has raised a total of $23.8M (USD).

How many employees does Sentieon have?

Sentieon has 13 employees as of Feb 4, 2024.

Sentieon - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
  • Cloud
  • SaaS
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Usage-based
Customer
  • Enterprise
Main Product
  • Bioinformatics
  • Genomics
Tags
  • Platform
  • Software
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software